WO2023277224A1 - Antioxidant composition comprising oriental medicinal extract containing aurea helianthus, and herbal medicine extract - Google Patents

Antioxidant composition comprising oriental medicinal extract containing aurea helianthus, and herbal medicine extract Download PDF

Info

Publication number
WO2023277224A1
WO2023277224A1 PCT/KR2021/008381 KR2021008381W WO2023277224A1 WO 2023277224 A1 WO2023277224 A1 WO 2023277224A1 KR 2021008381 W KR2021008381 W KR 2021008381W WO 2023277224 A1 WO2023277224 A1 WO 2023277224A1
Authority
WO
WIPO (PCT)
Prior art keywords
extract
composition
weight
parts
geumhwagyu
Prior art date
Application number
PCT/KR2021/008381
Other languages
French (fr)
Korean (ko)
Inventor
박남완
박준호
Original Assignee
주식회사 네이처 보타닉스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 네이처 보타닉스 filed Critical 주식회사 네이처 보타닉스
Priority to PCT/KR2021/008381 priority Critical patent/WO2023277224A1/en
Publication of WO2023277224A1 publication Critical patent/WO2023277224A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9794—Liliopsida [monocotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Definitions

  • the present invention relates to an antioxidant composition and an anti-aging composition containing a herbal extract and a crude drug extract containing Geumhwagyu.
  • endogenous factors include a decrease or irregularity in the secretion of various hormones related to metabolic regulation, a decrease in protein biosynthesis such as collagen due to a decrease in cell activity, accumulation of pollutants in the body due to a decrease in circulatory function, and metabolism in the body. Excessive accumulation of active oxygen, etc.
  • extrinsic factors include an increase in free radicals and active oxygen in the body due to exposure of the skin to ultraviolet rays, smoking, and environmental pollution.
  • the skin of the human body undergoes a skin aging phenomenon that exhibits symptoms such as decrease in elasticity and thickness, increase in wrinkles, disruption of oil-moisture balance, pigmentation such as melasma and freckles, and age spots.
  • Patent Document 1 KR 10-2021-0051512 A
  • an object of the present invention is to provide a composition with excellent antioxidant effect.
  • an object of the present invention is to provide a composition having an excellent anti-aging effect.
  • an object of the present invention is to fundamentally control skin oxidation and aging.
  • an object of the present invention is to provide an optimal combination of herbal extracts and herbal extracts capable of maximizing antioxidant and anti-aging effects.
  • an object of the present invention is to provide a cosmetic composition with excellent formulation stability and feeling of use.
  • geumhwagyu extract in one aspect, geumhwagyu extract; and at least one of chestnut extract, green tea extract, sea bamboo shoot extract, gondre extract, and marjoram extract as an active ingredient.
  • geumhwagyu extract in one aspect, provides a composition for improving skin wrinkles, comprising at least one of chestnut extract, green tea extract, sea bamboo shoot extract, gondre extract, and marjoram extract as an active ingredient.
  • geumhwagyu extract in one aspect, provides an anti-inflammatory composition comprising at least one of chestnut extract, green tea extract, haejuksun extract, gondre extract, and marjoram extract as an active ingredient.
  • the composition containing herbal extracts such as Geumhwagyu and crude drug extracts, has excellent electron donating ability, radical scavenging ability, activity inhibitory activity of elastase and collagenase, and ability to inhibit the production of active oxygen and PGE 2 Therefore, it has excellent antioxidant, skin wrinkle improvement and anti-inflammatory effects, and is harmless to the human body because it is non-toxic. Therefore, the composition can be usefully used in cosmetics for improving skin condition, food or medicine for improving diseases caused by oxidation and inflammation.
  • the present invention is geumhwagyu extract; and at least one of chestnut extract, green tea extract, haejuksun extract, gondre extract, and marjoram extract as an active ingredient.
  • the present invention is geumhwagyu extract; and at least one of a chestnut extract, a green tea extract, a sea bamboo shoot extract, a gondre extract, and a cornflower extract as an active ingredient, a composition for improving skin wrinkles.
  • the present invention is geumhwagyu extract; and at least one of chestnut extract, green tea extract, haejuksun extract, gondre extract, and marjoram extract as an active ingredient.
  • Geumhwagyu Hibiseu Smanihot L.
  • the flowers of Geumhwagyu are non-toxic and are effective in antipyretic, blood loss, detoxification, moist heat, and sore throat pain relief, and are prescribed for nausea, swelling, burns, etc., and the seeds strengthen the stomach and spleen to treat indigestion and strengthen muscles. It is described to develop and treat bruises.
  • flavone As revealed through modern medicine, flavone, which is abundantly contained in the flower of Geumhwagyu, has treatment for pain relief, anticerebral hemorrhage, and oral ulcers, and strengthens immunity and improves cardiovascular/cerebrovascular and capillary vessels by regulating the endocrine system of the human body. It is known to improve the blood circulation of the human body and has effects such as antioxidant, anti-fatigue, anti-aging, and anti-cancer effects. Geumhwagyu is rich in natural phytoestrogens, so it is effective for menopause and has been known to promote the production of male hormones.
  • extract includes all materials obtained by extracting components therein from natural products, regardless of the extraction method or the type of component. For example, it is a concept in a broad sense that includes all of those obtained by extracting a component soluble in a solvent from a natural product using water or an organic solvent, and extracting only a specific component of a natural product.
  • the composition may include geumhwagyu extract, chestnut extract, green tea extract, haejuksun extract, gondre extract, and marjoram extract as active ingredients.
  • the extract may include a crude extract, and may be included as a soluble fraction of the organic solvent obtained by further extracting the crude extract with an organic solvent having low polarity.
  • the extract or a soluble fraction of the extract may be used as it is, but may be concentrated after filtration and used in the form of an extract, and may be concentrated and then freeze-dried to be used in the form of a lyophilisate.
  • skin refers to an organ covering the outside of an organism, which is composed of epidermis, dermis, and subcutaneous fat layer, and includes not only tissues covering the outside of the face or the entire body, but also the scalp and hair in the broadest sense. to be.
  • antioxidant means an action of inhibiting oxidation.
  • prooxidants and antioxidants are in balance, but various factors cause this balance to become unbalanced.
  • ROS reactive oxygen species
  • Reactive nitrogen species such as NO, HNO2, and ONOO- are produced in large quantities due to immune responses of macrophages, neutrophils, and other immune cells during inflammatory reactions, and ROS are also produced at this time.
  • Active oxygen as described above oxidizes and destroys cells in the body, and thus is exposed to various diseases.
  • anti-inflammatory may mean an action of suppressing inflammation. It is known that the inflammatory response is originally intended to enhance and reduce damage of the repair system in vivo, but if the inflammatory response continues due to repeated tissue damage or regeneration, ROS and RNS are excessively produced in inflammation-related cells, resulting in permanent mutations in the human gene. As such, ROS and RNS are deeply related to the inflammatory response that regulates the actions of various cells in vivo.
  • ROS and RNS are deeply related to the inflammatory response that regulates the actions of various cells in vivo.
  • large amounts of the pro-inflammatory cytokines, nitric oxide (NO) and prostaglandin E2 (PGE 2 ) interact with inducible nitric oxide synthase (iNOS). It is produced by cyclooxygenase-2 (COX-2).
  • the geumhwagyu extract may include at least one of a flower extract, a leaf and stem extract, and a root extract of geumhwagyu.
  • the composition may include both a flower extract, a leaf and stem extract, and a root extract of Geumhwagyu, and in this case, the Geumhwagyu flower extract and leaf stem extract are each in order, 100 weight of root extract Based on parts, it may be included in 150 to 250 parts by weight and 50 to 150 parts by weight.
  • the flower extract based on 100 parts by weight of the root extract, may be included in 170 to 230 parts by weight, or 190 to 210 parts by weight.
  • the leaf stem extract may be included in 70 to 130 parts by weight or 90 to 110 parts by weight based on 100 parts by weight of the root extract.
  • the geumhwagyu extract may be included in 10 to 40% by weight based on the total weight of the composition.
  • the gold flower extract may be included in 5 to 25% by weight, or 8 to 23% by weight, or 8 to 12% by weight based on the total weight of the composition.
  • the gold leaf stem extract may be included in 1 to 15% by weight, or 3 to 12% by weight, or 3 to 7% by weight based on the total weight of the composition.
  • the Geumhwagyu root extract may be included in 1 to 15% by weight, or 3 to 12% by weight, or 3 to 7% by weight based on the total weight of the composition.
  • the composition may further include at least one of a grape extract and an eggplant extract.
  • the chestnut extract may include an extract of the skin of the chestnut, that is, Yulpi.
  • the chestnut extract and green tea extract may each be included in 5 to 30% by weight based on the total weight of the composition. Specifically, the chestnut extract and green tea extract may be included in 8 to 25% by weight, or 15 to 25% by weight, or 18 to 22% by weight, respectively, based on the total weight of the composition.
  • the chestnut extract and green tea extract may be included in 10 to 200 parts by weight, 50 to 150 parts by weight, or 70 to 130 parts by weight, respectively, based on 100 parts by weight of the geumhwagyu extract.
  • sea bamboo shoot extract and the gondre extract may be included in 5 to 25% by weight, respectively, based on the total weight of the composition, or 5 to 20% by weight, or 5 to 15% by weight, or 8 to 12% by weight % can be included.
  • the Haejuksun extract and the Gondre extract may be included in 10 to 100 parts by weight, 30 to 70 parts by weight, or 40 to 60 parts by weight based on 100 parts by weight of the Geumhwagyu extract.
  • the mazac cord extract may be included in 1 to 15% by weight, or 3 to 12% by weight, or 3 to 10% by weight, or 3 to 7% by weight based on the total weight of the composition.
  • the mazak string extract may be included in 1 to 50 parts by weight, or 10 to 50 parts by weight, or 10 to 40 parts by weight, or 10 to 30 parts by weight, based on 100 parts by weight of the Geumhwagyu extract.
  • the grape extract may be included in 5 to 25% by weight based on the total weight of the composition, or 5 to 20% by weight, or 5 to 15% by weight, or 7 to 13% by weight.
  • the grape extract may be included in 10 to 100 parts by weight, or 30 to 70 parts by weight, or 40 to 60 parts by weight, based on 100 parts by weight of the Keumhwagyu extract.
  • the eggplant extract may be included in 1 to 50 parts by weight, or 10 to 50 parts by weight, or 10 to 40 parts by weight, or 10 to 30 parts by weight, based on 100 parts by weight of the Geumhwagyu extract.
  • the extraction solvent of the extract may include water, an organic solvent, or an organic solvent aqueous solution.
  • the organic solvent, hexane, methylene chloride, alcohol, etc. may be used as the organic solvent, but is not limited thereto.
  • the water includes distilled water or purified water
  • the organic solvent is a group consisting of ethanol, acetone, ether, ethyl acetate, diethyl ether, methanol, ethyl methyl ketone and chloroform, for example, lower alcohols of C 1 ⁇ C 5 It may include one or more selected from, and may preferably be ethanol, but is not limited thereto.
  • the effect of the composition may be better when about 60 to 80% (v / v) of ethanol is used as an extraction solvent than that of the hot water extract.
  • the composition may include a food composition or a cosmetic composition, but is not limited thereto.
  • the cosmetic composition may contain a cosmetically acceptable medium or base.
  • a cosmetically acceptable medium or base for example solutions, gels, solid or pasty anhydrous products, emulsions obtained by dispersing an oily phase in an aqueous phase, suspensions, microemulsions, microcapsules, microgranules or ionic forms (liposomes) and/or It may be provided in the form of a non-ionic follicular dispersant, or in the form of a cream, toner, lotion, powder, ointment, spray or conceal stick.
  • These compositions can be prepared according to conventional methods in the art.
  • a solvent, solubilizing agent or emulsifying agent is used as a carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 ,3-butyl glycol oil, fatty acid esters of glycerol, polyethylene glycol or sorbitan.
  • the formulation of the present invention is a suspension
  • a liquid diluent such as water, ethanol or propylene glycol, an ethoxylated isostearyl alcohol, a suspending agent such as polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, microcrystals Star cellulose, aluminum metahydroxide, bentonite, agar or tracanth and the like
  • a suspending agent such as polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, microcrystals Star cellulose, aluminum metahydroxide, bentonite, agar or tracanth and the like may be used.
  • the formulation of the present invention is a paste, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, tracanth, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide may be used as a carrier component.
  • lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component, and in particular, in the case of a spray, additional chlorofluorohydrocarbon, propane / May contain a propellant such as butane or dimethyl ether.
  • the cosmetic composition may additionally contain a thickening agent.
  • the thickening agent included in the cosmetic composition of the present invention is, for example, methyl cellulose, carboxy methyl cellulose, carboxy methyl hydroxyguanine, hydroxy methyl cellulose, hydroxyethyl cellulose, carboxy vinyl polymer, polyquaternium, cetearyl alcohol, stearate Lyric acid, carrageenan, and the like can be used.
  • the cosmetic composition may contain various appropriate bases and additives as needed, and the types and amounts of these components can be easily selected by the inventor. Acceptable additives may be included as needed, and for example, components such as preservatives and pigments common in the art may be further included.
  • blending components that may be added other than these are not limited thereto, and any of the above components can be blended within a range not impairing the objects and effects of the present invention.
  • the cosmetic composition may include an ampoule or cream, but is not limited thereto.
  • the cosmetic composition, ampoule, skin softener, toner, astringent, lotion, massage cream, nutrient cream, moisture cream, hand cream, foundation, essence, nutrient lotion, pack, soap, cleansing foam, cleansing lotion, cleansing cream It may be any one or more selected from the group consisting of body lotion and body cleanser.
  • the formulation of the cream may be W/S, W/O, P/W, W/O/W, or O/W/O.
  • the cosmetic composition when the cream formulation is W / S, may include alcohols, glycerin, dimethicone, silicone, and acrylates. Specifically, when the cream formulation is W/S, it may include the composition shown in Table 1 below.
  • the cosmetic composition when it is an ampoule, it may include 1,3-butylene glycol, 1,2-hexanediol, dipotassium glycyrrhizate, thickener, peptides, and the like. Specifically, it is as described in Table 2 below.
  • ingredient Content (% by weight) Purified water balance 1,3-butylene glycol 1 to 3 peptides 0.1 to 1 hyaluronic acid 1 to 5 D-panthenol 1 to 10 1,2-hexanediol Appropriate amount dipotassium glycyrrhizate 0.01 ⁇ 0.05 Ethylhexylglycerin Appropriate amount capopol 5 to 15 composition 1 to 10
  • the ampoule exhibits a viscosity similar to that of water and may have excellent spreadability.
  • the ampoule is free from stickiness and shine, and has excellent durability.
  • the cream imparts a light adherence when applied to the skin, has excellent skin absorption, penetrates into the skin moistly, and finally provides a smooth and non-sticky softness.
  • the ampoules and creams are less denatured by temperature and have excellent storage stability because there is no component separation.
  • Geumhwagyu (flower, leaf stem, root), yulpi, green tea, sea bamboo shoot, gondre, marsak string, grape, and eggplant are primarily crushed using a mixer, and then 70% ethanol of 10 times the sample weight is added to each. Soaked at room temperature for 24 hours and extracted three times. Each extract was lyophilized after filtration and concentration.
  • a composition was prepared by mixing the prepared plant extracts in the content ratios shown in Table 3 below.
  • 1,1-diphenyl-2-picrylhydrazyl is a chemically stabilized water-soluble free radical, a purple compound showing characteristic light absorption at 517 nm, and is very stable in organic solvents such as alcohol. When it meets a substance with antioxidant activity, it gives up electrons and radicals (DPPH) are annihilated, and the color changes from purple in the initial solution to yellow, so the oxidation activity can be easily observed with the naked eye, which is a representative substance used in antioxidant activity experiments. to be.
  • Elastase inhibition was measured at 405 nm for the amount of p-nitroanilide generated from the substrate at 37° C. for 20 minutes using N-succinyl-(L-Ala) 3 -p-nitroanilide as a substrate.
  • each test solution is taken in a test tube at a certain concentration
  • 0.5 mL of a solution of porcine pancreas elastase (2.5 U/mL) dissolved in 50 mM tris-HCl buffer (pH 8.6) is added, and 50 mM tris as a substrate N-succinyl-(L-Ala) 3 -p-nitroanilide (0.5 mg/mL) dissolved in -HCl buffer (pH 8.6) was added and reacted for 20 minutes to measure.
  • the elastase inhibitory ability was expressed as the rate of decrease in absorbance of the sample solution added group and non-added group.
  • Collagenase inhibition was measured by adding 4 mM CaCl 2 to 0.1 M tris-HCl buffer (pH 7.5), 0.25 mL of a substrate solution in which 4-phenylazobenzyloxycarbonyl-Pro-Leu-Gly-Pro-D-Arg (0.3 mg/mL) was dissolved. After adding 0.15 mL of collagenase (0.2 mg/mL) to the mixture of 0.1 mL of sample solution and 0.1 mL of sample solution, leave it at room temperature for 20 minutes, stop the reaction by adding 0.5 mL of 6% citric acid, and add 1.5 mL of ethyl acetate to 320 nm. The absorbance was measured at. The collagenase inhibitory ability was expressed as the rate of decrease in absorbance of the sample solution added group and non-added group.
  • Macrophage (Raw 264.7) viability was confirmed with respect to the composition of Preparation Example. As a result, cell viability of 80.2% or more was confirmed at concentrations of 10, 100, and 1000 ⁇ g/ml. Based on the results of this experiment, the following experiment was performed by treating the composition with a concentration of 100 ⁇ g / ml or less, which had a cell viability of 90.1%.
  • Mouse macrophage cell line Raw 264.7 (mouse macrophage cell line RAW 264.7) was treated with lipopolysaccharide (LPS), a macrophage stimulating factor, to induce NO production, an inflammatory substance, and the composition of Preparation Example was 1, 5, 10, 100 ⁇ g/ml treated for 24 hours. Thereafter, a Griess reagent was added and reacted for 10 minutes, and NO generation was measured at a wavelength of 540 nm using a microplate-ELISA reader. As a result, when treated at a concentration of 100 ⁇ g/ml, 51.6% of NO was measured, confirming that 48.4% of NO production inhibition was present. For reference, when treated with 100 ⁇ g/ml of EGCG as a control, it was confirmed that the composition of the present invention exhibited an effect of inhibiting NO production by about 73% compared to EGCG.
  • LPS lipopolysaccharide
  • PGE 2 is an inflammatory mediator mainly involved in the transmission of pain and fever in damaged areas or tissues.
  • Raw 264.7 cells were adjusted to 5 ⁇ 10 4 cells/mL, seeded in a 96-well plate, and pre-incubated for 24 hours. Cells were simultaneously treated with 1 ⁇ g/mL of LPS and the extract and cultured for 24 hours.
  • the secretion of PGE 2 cytokine in the cell culture medium was measured using an enzyme linked immunosorbent assay (ELISA) kit (R&D Systems, Minneapolis, MN, USA) did 100 ⁇ l each of the culture medium was loaded onto a 96-well plate coated with goat anti-mouse, and 50 ⁇ l of primary antibody solution and 50 ⁇ l of PGE 2 conjugate were added, followed by shaking at 500 rpm and reacting at room temperature for 2 hours. After that, it was washed 4 times with Washing buffer, treated with substrate solution, and absorbance was measured at 450 nm.
  • ELISA enzyme linked immunosorbent assay

Abstract

The present invention relates to an antioxidant composition and an anti-aging composition, comprising: an oriental medicinal extract containing Aurea helianthus; and a herbal medicine extract. A composition comprising an oriental medicinal extract such as Aurea helianthus and a herbal medicine extract, according to one aspect of the present invention, has excellent electron donating ability and radical scavenging ability, activity inhibiting power of elastase and collagenase, and active oxygen and PGE2 generation inhibiting power, and thus has excellent antioxidant, skin wrinkle improvement and anti-inflammatory effects, and is harmless to the human body because of non-toxicity. Therefore, the composition can be usefully used in cosmetics for improving skin condition, and in food or medicine for improving diseases caused by oxidation and inflammation.

Description

금화규를 포함하는 한방 추출물 및 생약 추출물을 포함하는 항산화용 조성물Antioxidant Composition Containing Herbal Extract and Herbal Medicine Extract Containing Geumhwagyu
본 발명은 금화규를 포함하는 한방 추출물 및 생약 추출물을 포함하는 항산화용 조성물 및 항노화용 조성물에 관한 것이다.The present invention relates to an antioxidant composition and an anti-aging composition containing a herbal extract and a crude drug extract containing Geumhwagyu.
인체의 피부는 나이가 들어감에 따라 다양한 내인성 요인과 외인성 요인에 의해 변화를 겪는다.Human skin undergoes changes due to various endogenous and extrinsic factors as it ages.
구체적으로, 내인성 요인으로는, 신진대사 조절과 관련된 각종 호르몬의 분비의 감소 또는 불규칙화, 세포의 활성 저하에 따른 콜라겐 등 단백질 생합성 감소, 순환 기능 저하에 따른 오염 물질 체내 축적, 체내 물질 대사에 의햔 활성 산소의 과량 축적 등이 있다. 또한, 외인성 요인으로는 피부의 자외선 노출에 따른 체내 자유 라디칼 및 활성 산소 증가, 흡연, 환경 오염 등이 있다. 이러한 내인성 요인과 외인성 요인에 의해, 인체의 피부는 탄력과 두께의 감소, 주름의 증가, 유수분 밸런스의 붕괴, 기미, 주근깨 등 색소 침착, 검버섯 등과 같은 증상을 나타내는 피부 노화 현상을 겪게된다. Specifically, endogenous factors include a decrease or irregularity in the secretion of various hormones related to metabolic regulation, a decrease in protein biosynthesis such as collagen due to a decrease in cell activity, accumulation of pollutants in the body due to a decrease in circulatory function, and metabolism in the body. Excessive accumulation of active oxygen, etc. In addition, extrinsic factors include an increase in free radicals and active oxygen in the body due to exposure of the skin to ultraviolet rays, smoking, and environmental pollution. Due to these endogenous and extrinsic factors, the skin of the human body undergoes a skin aging phenomenon that exhibits symptoms such as decrease in elasticity and thickness, increase in wrinkles, disruption of oil-moisture balance, pigmentation such as melasma and freckles, and age spots.
한편, 현대사회에 들어서면서 의학의 발전으로 인해 인간의 평균 수명이 증가하고, 웰빙에 대한 열망이 증가하면서, 피부 노화와 이를 개선할 수 있는 방안에 대한 일반인들의 관심이 높아지고 있다. 이에, 최근에는 플라보노이드, 토코페롤 등의 항산화 및 항노화 효과가 있다고 알려진 성분을 다량 포함하고 있는 생약과 한방 물질에 대한 연구가 활발히 이루어지고 있고, 실제로 다양한 생약 및 한방 물질이 밝혀진바 있으며, 이들을 조합하여 제조한 조성에 대한 연구도 계속되고 있다.On the other hand, as the average lifespan of humans increases and the desire for well-being increases due to the development of medicine in modern society, the general public's interest in skin aging and ways to improve it is increasing. Therefore, in recent years, studies on herbal medicines and herbal substances containing a large amount of components known to have antioxidant and anti-aging effects, such as flavonoids and tocopherols, have been actively conducted. Research on the prepared composition is also continuing.
그러나, 아직까지 만족할만한 효과를 거둔 생약 및 한방 물질의 조합은 밝혀진바 없다.However, a combination of herbal medicine and oriental medicine material that has a satisfactory effect has not yet been identified.
<선행기술문헌><Prior art literature>
(특허문헌 1) KR 10-2021-0051512 A(Patent Document 1) KR 10-2021-0051512 A
일 측면에서, 본 발명의 목적은 항산화 효과가 우수한 조성물을 제공하는 것이다.In one aspect, an object of the present invention is to provide a composition with excellent antioxidant effect.
일 측면에서, 본 발명의 목적은 항노화 효과가 우수한 조성물을 제공하는 것이다.In one aspect, an object of the present invention is to provide a composition having an excellent anti-aging effect.
일 측면에서, 본 발명의 목적은 피부 산화 및 노화를 근본적으로 제어하는 것이다.In one aspect, an object of the present invention is to fundamentally control skin oxidation and aging.
일 측면에서, 본 발명의 목적은 항산화 및 항노화 효과를 극대화할 수 있는 한방 추출물과, 생약 추출물의 최적의 조합을 제공하는 것이다.In one aspect, an object of the present invention is to provide an optimal combination of herbal extracts and herbal extracts capable of maximizing antioxidant and anti-aging effects.
일 측면에서, 본 발명의 목적은 제형 안정성과 사용감이 우수한 화장료 조성물을 제공하는 것이다.In one aspect, an object of the present invention is to provide a cosmetic composition with excellent formulation stability and feeling of use.
상기 목적을 달성하기 위하여, 본 발명은 일 측면에서, 금화규 추출물; 및 밤 추출물, 녹차 추출물, 해죽순 추출물, 곤드레 추출물, 마삭줄 추출물 중 하나 이상을 유효 성분으로 포함하는, 항산화용 조성물을 제공한다.In order to achieve the above object, the present invention, in one aspect, geumhwagyu extract; and at least one of chestnut extract, green tea extract, sea bamboo shoot extract, gondre extract, and marjoram extract as an active ingredient.
상기 목적을 달성하기 위하여, 본 발명은 일 측면에서, 금화규 추출물; 및 밤 추출물, 녹차 추출물, 해죽순 추출물, 곤드레 추출물, 마삭줄 추출물 중 하나 이상을 유효 성분으로 포함하는, 피부 주름 개선용 조성물을 제공한다.In order to achieve the above object, the present invention, in one aspect, geumhwagyu extract; And it provides a composition for improving skin wrinkles, comprising at least one of chestnut extract, green tea extract, sea bamboo shoot extract, gondre extract, and marjoram extract as an active ingredient.
상기 목적을 달성하기 위하여, 본 발명은 일 측면에서, 금화규 추출물; 및 밤 추출물, 녹차 추출물, 해죽순 추출물, 곤드레 추출물, 마삭줄 추출물 중 하나 이상을 유효 성분으로 포함하는, 항염증용 조성물을 제공한다.In order to achieve the above object, the present invention, in one aspect, geumhwagyu extract; And it provides an anti-inflammatory composition comprising at least one of chestnut extract, green tea extract, haejuksun extract, gondre extract, and marjoram extract as an active ingredient.
본 발명의 일 측면인 금화규 등의 한방 추출물과 생약 추출물을 포함하는 조성물은, 전자공여능 및 라디컬 소거능, 엘라스타아제 및 콜라게나아제의 활성 저해력, 활성산소 및 PGE2의 생성 억제력이 우수하므로, 항산화, 피부 주름 개선 효과 및 항염증 효과가 우수하고, 독성이 없어 인체에 무해하다. 따라서, 상기 조성물은 피부 상태 개선을 위한 화장품, 산화 및 염증 작용에 의해 유발되는 질환의 개선을 위한 식품이나 의약품 등에 유용하게 이용될 수 있다.One aspect of the present invention, the composition containing herbal extracts such as Geumhwagyu and crude drug extracts, has excellent electron donating ability, radical scavenging ability, activity inhibitory activity of elastase and collagenase, and ability to inhibit the production of active oxygen and PGE 2 Therefore, it has excellent antioxidant, skin wrinkle improvement and anti-inflammatory effects, and is harmless to the human body because it is non-toxic. Therefore, the composition can be usefully used in cosmetics for improving skin condition, food or medicine for improving diseases caused by oxidation and inflammation.
이하에서, 각 구성을 보다 상세히 설명하나, 이는 하나의 예시에 불과할 뿐, 본 발명의 권리범위가 다음 내용에 의해 제한되지 아니한다.Hereinafter, each configuration will be described in more detail, but this is only one example, and the scope of the present invention is not limited by the following content.
본 발명의 명세서 및 청구범위에 사용된 용어 또는 단어는 통상적이거나 사전적인 의미로 한정 해석되지 아니하며, 발명자는 그 자신의 발명을 가장 최선의 방법으로 설명하기 위해 용어의 개념을 적절하게 정의할 수 있다는 원칙에 입각하여 본 발명의 기술적 사상에 부합하는 의미와 개념으로 해석되어야만 한다.Terms or words used in the specification and claims of the present invention are not limited to the usual or dictionary meaning, and the inventor can properly define the concept of the term in order to explain his/her invention in the best way. Based on the principle, it should be interpreted as a meaning and concept consistent with the technical idea of the present invention.
본 발명의 명세서 전체에 있어서, 어떤 부분이 어떤 구성 요소를 "포함" 한다고 할 때, 이는 특별히 반대되는 기재가 없는 한 다른 구성 요소를 제외하는 것이 아니라 다른 구성 요소를 더 포함할 수 있는 것을 의미한다.Throughout the specification of the present invention, when a part "includes" a certain component, it means that it may further include other components, not excluding other components unless otherwise stated. .
일 측면에서, 본 발명은 금화규 추출물; 및 밤 추출물, 녹차 추출물, 해죽순 추출물, 곤드레 추출물, 및 마삭줄 추출물 중 하나 이상을 유효 성분으로 포함하는, 항산화용 조성물이다.In one aspect, the present invention is geumhwagyu extract; and at least one of chestnut extract, green tea extract, haejuksun extract, gondre extract, and marjoram extract as an active ingredient.
또한, 일 측면에서, 본 발명은 금화규 추출물; 및 밤 추출물, 녹차 추출물, 해죽순 추출물, 곤드레 추출물, 및 마삭줄 추출물 중 하나 이상을 유효 성분으로 포함하는, 피부 주름 개선용 조성물이다.In addition, in one aspect, the present invention is geumhwagyu extract; and at least one of a chestnut extract, a green tea extract, a sea bamboo shoot extract, a gondre extract, and a cornflower extract as an active ingredient, a composition for improving skin wrinkles.
또한, 일 측면에서, 본 발명은 금화규 추출물; 및 밤 추출물, 녹차 추출물, 해죽순 추출물, 곤드레 추출물, 및 마삭줄 추출물 중 하나 이상을 유효 성분으로 포함하는, 항염증용 조성물이다.In addition, in one aspect, the present invention is geumhwagyu extract; and at least one of chestnut extract, green tea extract, haejuksun extract, gondre extract, and marjoram extract as an active ingredient.
금화규(Hibiseu Smanihot L.)는, 아욱과에 속하는 1년생 초본 식물로, 황금 해바라기 또는 히브스커스라고 불리기도 한다. 본초강목에서 금화규의 꽃은 무독하며 해열, 양혈, 해독, 습열, 소담 진통에 효능이 있고, 오림, 부종, 화상 등에 처방하며, 종자는 위와 비장을 튼튼하게 하여 소화불량을 치료하고, 근육을 발달시키며, 타박상을 치료한다고 기술되어 있다. 현대 의학을 통해 밝혀진 바로는 금화규의 꽃에 풍부하게 함유된 플라본(flavone)에 의해 진통, 항뇌결혈과 구강궤양 등의 치료가 있으며, 인체의 내분비 조절로 면역력 증강과 심/뇌혈관 및 모세혈관의 혈액 순환을 개선시키고, 인체의 항산화, 항피로, 항노화, 항암 등의 효능이 있다고 알려져 있다. 금화규에는 천연 식물성 에스트로겐이 풍부하여 갱년기에 효력이 있으며, 남성 호르몬의 생성을 촉진하는 효과가 있는 것으로 알려진 바 있다.Geumhwagyu ( Hibiseu Smanihot L. ) is an annual herbaceous plant belonging to Malvaceae, and is also called golden sunflower or hibiscus. In herbal medicine, the flowers of Geumhwagyu are non-toxic and are effective in antipyretic, blood loss, detoxification, moist heat, and sore throat pain relief, and are prescribed for nausea, swelling, burns, etc., and the seeds strengthen the stomach and spleen to treat indigestion and strengthen muscles. It is described to develop and treat bruises. As revealed through modern medicine, flavone, which is abundantly contained in the flower of Geumhwagyu, has treatment for pain relief, anticerebral hemorrhage, and oral ulcers, and strengthens immunity and improves cardiovascular/cerebrovascular and capillary vessels by regulating the endocrine system of the human body. It is known to improve the blood circulation of the human body and has effects such as antioxidant, anti-fatigue, anti-aging, and anti-cancer effects. Geumhwagyu is rich in natural phytoestrogens, so it is effective for menopause and has been known to promote the production of male hormones.
본 명세서에서 "추출물" 은, 천연물로부터 그 안의 성분을 뽑아냄으로써 얻어진 물질이라면, 뽑아내는 방법이나 성분의 종류와 무관하게 모두 포함한다. 예컨대, 물이나 유기 용매를 이용하여 천연물로부터 용매에 용해되는 성분을 추출해 낸 것, 천연물의 특정 성분만을 추출하여 얻어진 것 등을 모두 포함하는 광의의 개념이다. In this specification, "extract" includes all materials obtained by extracting components therein from natural products, regardless of the extraction method or the type of component. For example, it is a concept in a broad sense that includes all of those obtained by extracting a component soluble in a solvent from a natural product using water or an organic solvent, and extracting only a specific component of a natural product.
일 측면에서, 상기 조성물은 금화규 추출물, 밤 추출물, 녹차 추출물, 해죽순 추출물, 곤드레 추출물, 및 마삭줄 추출물을 유효 성분으로 포함할 수 있다.In one aspect, the composition may include geumhwagyu extract, chestnut extract, green tea extract, haejuksun extract, gondre extract, and marjoram extract as active ingredients.
본 명세서에서 추출물은 조추출물을 포함할 수 있고, 상기 조추출물을 극성이 낮은 유기 용매로 더욱 추출하여 얻어진 유기 용매의 가용성 분획물로서 포함할 수도 있다. 상기 추출물 또는 그 추출물의 가용성 분획물은 그대로 사용할 수도 있으나, 여과 후 농축하여 엑기스 형태로 사용할 수 있으며, 농축 후 동결 건조하여 동결건조물의 형태로서 사용할 수 있다.In the present specification, the extract may include a crude extract, and may be included as a soluble fraction of the organic solvent obtained by further extracting the crude extract with an organic solvent having low polarity. The extract or a soluble fraction of the extract may be used as it is, but may be concentrated after filtration and used in the form of an extract, and may be concentrated and then freeze-dried to be used in the form of a lyophilisate.
본 명세서에서 "피부"는 생물의 외부를 덮고 있는 기관을 의미하는 것으로서 표피, 진피 및 피하지방층으로 구성되어 있으며 얼굴 또는 몸 전체의 외부를 덮는 조직뿐만 아니라, 두피와 모발을 포함하는 최광의의 개념이다.In this specification, "skin" refers to an organ covering the outside of an organism, which is composed of epidermis, dermis, and subcutaneous fat layer, and includes not only tissues covering the outside of the face or the entire body, but also the scalp and hair in the broadest sense. to be.
본 명세서에서 "항산화"는 산화를 억제하는 작용을 의미하는 것으로, 인체는 산화촉진물질(prooxidant)과 산화억제물질(antioxidant)이 균형을 이루고 있으나 여러 가지 요인들에 의하여 이런 균형상태가 불균형을 이루게되고 산화촉진 쪽으로 기울게 되면, 산화적 스트레스(oxidative stress)가 유발되어 잠재적인 세포손상 및 병리적 질환을 일으키게 된다. 이러한 산화적 스트레스의 직접적 원인이 되는 활성산소종(reactive oxygen species, ROS)은 불안정하고 반응성이 높아 여러 생체물질과 쉽게 반응하고, 체내 고분자들을 공격하여 세포와 조직에 비가역적인 손상을 일으키거나 돌연변이, 세포독성 및 발암 등을 초래하게 된다. NO, HNO2, ONOO-와 같은 활성질소종(reactive nitrogen species, RNS)은 염증 반응 시 대식세포 호중구 및 다른 면역 세포 들의 면역반응으로 인해 다량 생성되며, 이때 ROS도 같이 생성된다. 상기와 같은 활성산소는 체내에서 세포를 산화시켜 파괴시키며, 그에 따라 각종 질환에 노출되게 된다. As used herein, "antioxidation" means an action of inhibiting oxidation. In the human body, prooxidants and antioxidants are in balance, but various factors cause this balance to become unbalanced. When it is inclined toward oxidation promotion, oxidative stress is induced, resulting in potential cell damage and pathological diseases. Reactive oxygen species (ROS), which is a direct cause of such oxidative stress, are unstable and highly reactive, easily reacting with various biomaterials, and attacking macromolecules in the body to cause irreversible damage to cells and tissues, mutations, It causes cytotoxicity and carcinogenesis. Reactive nitrogen species (RNS) such as NO, HNO2, and ONOO- are produced in large quantities due to immune responses of macrophages, neutrophils, and other immune cells during inflammatory reactions, and ROS are also produced at this time. Active oxygen as described above oxidizes and destroys cells in the body, and thus is exposed to various diseases.
본 명세서에서 "항염증"은 염증를 억제하는 작용을 의미할 수 있다. 염증 반응은 본래 생체 내 복구체계의 증강 및 손상을 감소시키기 위한 것으로 알려져 있으나, 반복되는 조직의 손상이나 재생에 의해 염증반응이 지속되면, 염증관련 세포에서 ROS와 RNS가 과다 생성되고 그 결과로 영구적인 유전자의 변형이 야기된다. 이처럼 ROS와 RNS는 생체 내 여러 가지 세포의 작용을 조절하는 염증 반응과 깊이 관련되어 있다. 염증 과정 중에는 많은 양의 전염증성 사이토카인(pro-inflammatory cytokines), 일산화질소(nitric oxide, NO) 그리고 프로스타글란딘(prostaglandin E2, PGE2)이 유도성 일산화질소 합성효소 (inducible nitric oxide synthase, iNOS)와 사이클로옥시게나아제(cyclooxygenase-2, COX-2)에 의해 생성된다. As used herein, "anti-inflammatory" may mean an action of suppressing inflammation. It is known that the inflammatory response is originally intended to enhance and reduce damage of the repair system in vivo, but if the inflammatory response continues due to repeated tissue damage or regeneration, ROS and RNS are excessively produced in inflammation-related cells, resulting in permanent mutations in the human gene. As such, ROS and RNS are deeply related to the inflammatory response that regulates the actions of various cells in vivo. During the inflammatory process, large amounts of the pro-inflammatory cytokines, nitric oxide (NO) and prostaglandin E2 (PGE 2 ) interact with inducible nitric oxide synthase (iNOS). It is produced by cyclooxygenase-2 (COX-2).
일 측면에서, 상기 금화규 추출물은, 금화규의 꽃 추출물, 잎 및 줄기 추출물, 및 뿌리 추출물 중 하나 이상을 포함할 수 있다.In one aspect, the geumhwagyu extract may include at least one of a flower extract, a leaf and stem extract, and a root extract of geumhwagyu.
일 구현예에서, 상기 조성물은 금화규의 꽃 추출물, 잎 및 줄기 추출물, 및 뿌리 추출물을 모두 포함할 수 있고, 이 경우, 금화규 꽃 추출물 및 잎줄기 추출물은, 각각 순서대로, 뿌리 추출물 100 중량부를 기준으로, 150~250 중량부와 50~150 중량부로 포함될 수 있다. 구체적으로, 상기 꽃 추출물은, 뿌리 추출물 100 중량부를 기준으로, 170~230 중량부, 또는 190~210 중량부로 포함될 수 있다. 또한, 상기 잎줄기 추출물은, 뿌리 추출물 100 중량부를 기준으로, 70~130 중량부, 또는 90~110 중량부로 포함될 수 있다.In one embodiment, the composition may include both a flower extract, a leaf and stem extract, and a root extract of Geumhwagyu, and in this case, the Geumhwagyu flower extract and leaf stem extract are each in order, 100 weight of root extract Based on parts, it may be included in 150 to 250 parts by weight and 50 to 150 parts by weight. Specifically, the flower extract, based on 100 parts by weight of the root extract, may be included in 170 to 230 parts by weight, or 190 to 210 parts by weight. In addition, the leaf stem extract may be included in 70 to 130 parts by weight or 90 to 110 parts by weight based on 100 parts by weight of the root extract.
일 측면에서, 상기 금화규 추출물은 조성물 총 중량을 기준으로, 10~40 중량%로 포함될 수 있다. In one aspect, the geumhwagyu extract may be included in 10 to 40% by weight based on the total weight of the composition.
이 때, 상기 금화규 꽃 추출물은 조성물 총 중량을 기준으로 5~25 중량%, 또는 8~23 중량%, 또는 8~12 중량%로 포함될 수 있다.At this time, the gold flower extract may be included in 5 to 25% by weight, or 8 to 23% by weight, or 8 to 12% by weight based on the total weight of the composition.
또한, 상기 금화규 잎줄기 추출물은 조성물 총 중량을 기준으로 1~15 중량%, 또는 3~12 중량%, 또는 3~7 중량%로 포함될 수 있다.In addition, the gold leaf stem extract may be included in 1 to 15% by weight, or 3 to 12% by weight, or 3 to 7% by weight based on the total weight of the composition.
또한, 상기 금화규 뿌리 추출물은 조성물 총 중량을 기준으로 1~15 중량%, 또는 3~12 중량%, 또는 3~7 중량%로 포함될 수 있다.In addition, the Geumhwagyu root extract may be included in 1 to 15% by weight, or 3 to 12% by weight, or 3 to 7% by weight based on the total weight of the composition.
또한, 일 측면에서, 상기 조성물은 포도 추출물 및 가지(eggplant) 추출물 중 하나 이상을 더 포함할 수 있다.Also, in one aspect, the composition may further include at least one of a grape extract and an eggplant extract.
일 측면에서, 상기 밤 추출물은, 밤의 껍질, 즉 율피의 추출물을 포함할 수 있다.In one aspect, the chestnut extract may include an extract of the skin of the chestnut, that is, Yulpi.
일 측면에서, 상기 밤 추출물 및 녹차 추출물은 각각 조성물 총 중량을 기준으로 5~30 중량%로 포함될 수 있다. 구체적으로, 상기 밤 추출물 및 녹차 추출물은 각각 조성물 총 중량을 기준으로 8~25 중량%, 또는 15~25 중량%, 또는 18~22 중량%로 포함될 수 있다.In one aspect, the chestnut extract and green tea extract may each be included in 5 to 30% by weight based on the total weight of the composition. Specifically, the chestnut extract and green tea extract may be included in 8 to 25% by weight, or 15 to 25% by weight, or 18 to 22% by weight, respectively, based on the total weight of the composition.
또는, 상기 밤 추출물 및 녹차 추출물은 금화규 추출물을 100 중량부로 할 때, 각각 10~200 중량부, 또는 50~150 중량부, 또는 70~130 중량부로 포함될 수 있다.Alternatively, the chestnut extract and green tea extract may be included in 10 to 200 parts by weight, 50 to 150 parts by weight, or 70 to 130 parts by weight, respectively, based on 100 parts by weight of the geumhwagyu extract.
또한, 상기 해죽순 추출물 및 곤드레 추출물은, 각각 조성물 총 중량을 기준으로, 5~25 중량%로 포함될 수 있고, 또는 각각 5~20 중량%, 또는 각각 5~15 중량%, 또는 8~12 중량%로 포함될 수 있다.In addition, the sea bamboo shoot extract and the gondre extract may be included in 5 to 25% by weight, respectively, based on the total weight of the composition, or 5 to 20% by weight, or 5 to 15% by weight, or 8 to 12% by weight % can be included.
또는, 상기 해죽순 추출물 및 곤드레 추출물은, 금화규 추출물을 100 중량부로 할 때, 10~100 중량부, 또는 30~70 중량부, 또는 40~60 중량부로 포함될 수 있다.Alternatively, the Haejuksun extract and the Gondre extract may be included in 10 to 100 parts by weight, 30 to 70 parts by weight, or 40 to 60 parts by weight based on 100 parts by weight of the Geumhwagyu extract.
또한, 상기 마삭줄 추출물은, 조성물 총 중량을 기준으로 1~15 중량%로 포함될 수 있고, 또는 3~12 중량%, 또는 3~10 중량%, 또는 3~7 중량%로 포함될 수 있다.In addition, the mazac cord extract may be included in 1 to 15% by weight, or 3 to 12% by weight, or 3 to 10% by weight, or 3 to 7% by weight based on the total weight of the composition.
또는, 상기 마삭줄 추출물은, 금화규 추출물을 100 중량부로 할 때, 1~50 중량부, 또는 10~50 중량부, 또는 10~40 중량부, 또는 10~30 중량부로 포함될 수 있다.Alternatively, the mazak string extract may be included in 1 to 50 parts by weight, or 10 to 50 parts by weight, or 10 to 40 parts by weight, or 10 to 30 parts by weight, based on 100 parts by weight of the Geumhwagyu extract.
또한, 상기 포도 추출물은, 조성물 총 중량을 기준으로 5~25 중량%로 포함될 수 있고, 또는 5~20 중량%, 또는 5~15 중량%, 또는 7~13 중량%로 포함될 수 있다.In addition, the grape extract may be included in 5 to 25% by weight based on the total weight of the composition, or 5 to 20% by weight, or 5 to 15% by weight, or 7 to 13% by weight.
또는 상기 포도 추출물은, 금화규 추출물을 100 중량부로 할 때, 10~100 중량부, 또는 30~70 중량부, 또는 40~60 중량부로 포함될 수 있다.Alternatively, the grape extract may be included in 10 to 100 parts by weight, or 30 to 70 parts by weight, or 40 to 60 parts by weight, based on 100 parts by weight of the Keumhwagyu extract.
또한, 상기 가지 추출물은, 금화규 추출물을 100 중량부로 할 때, 1~50 중량부, 또는 10~50 중량부, 또는 10~40 중량부, 또는 10~30 중량부로 포함될 수 있다.In addition, the eggplant extract may be included in 1 to 50 parts by weight, or 10 to 50 parts by weight, or 10 to 40 parts by weight, or 10 to 30 parts by weight, based on 100 parts by weight of the Geumhwagyu extract.
일 측면에서, 상기 추출물의 추출용매는 물, 유기용매, 또는 유기용매 수용액을 포함할 수 있다.In one aspect, the extraction solvent of the extract may include water, an organic solvent, or an organic solvent aqueous solution.
일 측면에서, 상기 유기용매는, 유기 용매로는 헥산, 메틸렌클로라이드, 알코올 등이 이용될 수 있으나, 이에 한정되는 것은 아니다. 상기에서 물은 증류수 또는 정제수를 포함하고, 유기 용매는 C1~C5의 저급 알코올을 예로 들 수 있는 에탄올, 아세톤, 에테르, 에틸아세테이트, 디에틸에테르, 메탄올, 에틸메틸케톤 및 클로로포름으로 이루어진 군에서 선택된 하나 이상을 포함할 수 있고, 바람직하게는 에탄올일 수 있으나, 이에 제한되는 것은 아니다. In one aspect, the organic solvent, hexane, methylene chloride, alcohol, etc. may be used as the organic solvent, but is not limited thereto. In the above, the water includes distilled water or purified water, and the organic solvent is a group consisting of ethanol, acetone, ether, ethyl acetate, diethyl ether, methanol, ethyl methyl ketone and chloroform, for example, lower alcohols of C 1 ~ C 5 It may include one or more selected from, and may preferably be ethanol, but is not limited thereto.
일 구현예에서, 열수 추출물보다 약 60~80%(v/v)의 에탄올을 추출 용매로 사용할 때 조성물의 효과가 더 우수할 수 있다.In one embodiment, the effect of the composition may be better when about 60 to 80% (v / v) of ethanol is used as an extraction solvent than that of the hot water extract.
일 측면에서, 상기 조성물은, 식품 조성물 또는 화장료 조성물을 포함할 수 있으나, 이에 제한되는 것은 아니다.In one aspect, the composition may include a food composition or a cosmetic composition, but is not limited thereto.
상기 화장료 조성물은 화장품학적으로 허용가능한 매질 또는 기제를 함유할 수 있다. 이는 국소적용에 적합한 모든 제형으로, 예를 들면 용액, 겔, 고체 또는 반죽 무수 생성물, 수상에 유상을 분산시켜 얻은 에멀젼, 현탁액, 마이크로에멀젼, 마이크로캡슐, 미세과립구 또는 이온형(리포좀) 및/또는 비이온형의 소낭 분산제의 형태로, 또는 크림, 스킨, 로션, 파우더, 연고, 스프레이 또는 콘실 스틱의 형태로 제공될 수 있다. 이들 조성물은 당해 분야의 통상적 방법에 따라 제조될 수 있다.The cosmetic composition may contain a cosmetically acceptable medium or base. These are all formulations suitable for topical application, for example solutions, gels, solid or pasty anhydrous products, emulsions obtained by dispersing an oily phase in an aqueous phase, suspensions, microemulsions, microcapsules, microgranules or ionic forms (liposomes) and/or It may be provided in the form of a non-ionic follicular dispersant, or in the form of a cream, toner, lotion, powder, ointment, spray or conceal stick. These compositions can be prepared according to conventional methods in the art.
본 발명의 제형이 용액 또는 유탁액인 경우에는 담체 성분으로서 용매, 용해화제 또는 유탁화제가 이용되고, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌 글리콜, 1,3-부틸글리콜 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르가 있다.When the formulation of the present invention is a solution or emulsion, a solvent, solubilizing agent or emulsifying agent is used as a carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 ,3-butyl glycol oil, fatty acid esters of glycerol, polyethylene glycol or sorbitan.
본 발명의 제형이 현탁액인 경우에는 담체 성분으로서 물, 에탄올 또는 프로필렌 글리콜과 같은 액상의 희석제, 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 등이 이용될 수 있다.When the formulation of the present invention is a suspension, as a carrier component, a liquid diluent such as water, ethanol or propylene glycol, an ethoxylated isostearyl alcohol, a suspending agent such as polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, microcrystals Star cellulose, aluminum metahydroxide, bentonite, agar or tracanth and the like may be used.
본 발명의 제형이 페이스트, 크림 또는 겔인 경우에는 담체 성분으로서 동물성유, 식물성유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크 또는 산화아연 등이 이용될 수 있다.When the formulation of the present invention is a paste, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, tracanth, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide may be used as a carrier component. can
본 발명의 제형이 파우더 또는 스프레이인 경우에는 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록시드, 칼슘 실리케이트 또는 폴리아미드 파우더가 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판/부탄 또는 디메틸 에테르와 같은 추진체를 포함할 수 있다. When the formulation of the present invention is a powder or spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component, and in particular, in the case of a spray, additional chlorofluorohydrocarbon, propane / May contain a propellant such as butane or dimethyl ether.
상기 화장료 조성물은 추가적으로 점증제를 함유할 수 있다. 본 발명의 화장료 조성물에 포함되는 점증제는 예컨대, 메틸 셀룰로스, 카르복시 메틸 셀룰로스, 카르복시 메틸 하이드록시 구아닌, 하이드록시 메틸 셀룰로스, 하이드록시에틸셀룰로스, 카르복시 비닐 폴리머, 폴리쿼터늄, 세테아릴 알콜, 스테아릭산, 카라기난 등을 사용할 수 있다. The cosmetic composition may additionally contain a thickening agent. The thickening agent included in the cosmetic composition of the present invention is, for example, methyl cellulose, carboxy methyl cellulose, carboxy methyl hydroxyguanine, hydroxy methyl cellulose, hydroxyethyl cellulose, carboxy vinyl polymer, polyquaternium, cetearyl alcohol, stearate Lyric acid, carrageenan, and the like can be used.
또한, 상기 화장료 조성물은 필요에 따라 적절한 각종의 기제와 첨가제를 함유할 수 있으며, 이들 성분의 종류와 양은 발명자에 의해 용이하게 선정될 수 있다. 필요에 따라 허용 가능한 첨가제를 함유할 수 있으며, 예를 들면, 당업계에 통상적인 방부제, 색소 등의 성분을 추가로 포함할 수 있다.In addition, the cosmetic composition may contain various appropriate bases and additives as needed, and the types and amounts of these components can be easily selected by the inventor. Acceptable additives may be included as needed, and for example, components such as preservatives and pigments common in the art may be further included.
또한, 이외에 첨가해도 되는 배합 성분은 이에 한정되는 것은 아니며, 또, 상기 어느 성분도 본 발명의 목적 및 효과를 손상시키지 않는 범위 내에서 배합 가능하다.In addition, the blending components that may be added other than these are not limited thereto, and any of the above components can be blended within a range not impairing the objects and effects of the present invention.
일 측면에서, 상기 화장료 조성물은 앰플 또는 크림을 포함할 수 있으나, 이에 제한되는 것은 아니다. 예컨대, 상기 화장료 조성물은, 앰플, 스킨소프너, 토너, 아스트린젠트, 로션, 마사지크림, 영양크림, 모이스처크림, 핸드크림, 파운데이션, 에센스, 영양화장수, 팩, 비누, 클렌징폼, 클렌징로션, 클렌징크림, 바디로션 및 바디클린저로 이루어진 군으로부터 선택된 어느 하나 이상일 수 있다.In one aspect, the cosmetic composition may include an ampoule or cream, but is not limited thereto. For example, the cosmetic composition, ampoule, skin softener, toner, astringent, lotion, massage cream, nutrient cream, moisture cream, hand cream, foundation, essence, nutrient lotion, pack, soap, cleansing foam, cleansing lotion, cleansing cream, It may be any one or more selected from the group consisting of body lotion and body cleanser.
일 측면에서, 상기 화장료 조성물이 크림일 경우, 상기 크림의 제형은 W/S, W/O, P/W, W/O/W, 또는 O/W/O일 수 있다. In one aspect, when the cosmetic composition is a cream, the formulation of the cream may be W/S, W/O, P/W, W/O/W, or O/W/O.
일 측면에서, 상기 크림 제형이 W/S일 경우, 상기 화장료 조성물은, 알코올류, 글리세린류, 디메치콘류, 실리콘류, 및 아크릴레이트류를 포함할 수 있다. 구체적으로, 상기 크림 제형이 W/S일 경우, 아래 표 1과 같은 조성을 포함할 수 있다.In one aspect, when the cream formulation is W / S, the cosmetic composition may include alcohols, glycerin, dimethicone, silicone, and acrylates. Specifically, when the cream formulation is W/S, it may include the composition shown in Table 1 below.
성분ingredient 함량(중량%)Content (% by weight)
정제수Purified water 잔량balance
1,2-헥산디올1,2-hexanediol 1~3 1 to 3
글리세린 glycerin 0.1~20.1~2
에칠헥실글리세린Ethylhexylglycerin 0.01~0.10.01 to 0.1
디메치콘/PEG-10/15 크로스폴리머Dimethicone/PEG-10/15 Crosspolymer 5~155 to 15
디메치콘/비닐디메치콘 크로스폴리머Dimethicone/Vinyldimethicone Crosspolymer 1~101 to 10
사이클로펜타실록산cyclopentasiloxane 1~101 to 10
PEG-10 디메치콘PEG-10 dimethicone 적량Appropriate amount
폴리메칠메타크릴레이트polymethyl methacrylate 적량Appropriate amount
또한, 상기 화장료 조성물이 앰플일 경우엔, 1,3-부틸렌 글리콜, 1,2-헥산디올, 디포타슘 글리시리제이트, 점증제, 펩티드류 등을 포함할 수 있다. 구체적으로는 다음 표 2에 기재된 바와 같다.In addition, when the cosmetic composition is an ampoule, it may include 1,3-butylene glycol, 1,2-hexanediol, dipotassium glycyrrhizate, thickener, peptides, and the like. Specifically, it is as described in Table 2 below.
성분ingredient 함량(중량%)Content (% by weight)
정제수Purified water 잔량balance
1,3-부틸렌글리콜1,3-butylene glycol 1~3 1 to 3
펩티드류peptides 0.1~10.1 to 1
히알루론산hyaluronic acid 1~51 to 5
D-판테놀D-panthenol 1~101 to 10
1,2-헥산디올1,2-hexanediol 적량Appropriate amount
디포타슘 글리시리제이트dipotassium glycyrrhizate 0.01~0.050.01~0.05
에칠헥실글리세린Ethylhexylglycerin 적량Appropriate amount
카포폴capopol 5~155 to 15
조성물composition 1~101 to 10
일 측면에서, 상기 앰플은, 물과 유사한 점도를 나타내며, 펴발림성이 우수할 수 있다. 또한, 상기 앰플은 끈적임와 번들거림이 없으며, 지속력이 우수하다.In one aspect, the ampoule exhibits a viscosity similar to that of water and may have excellent spreadability. In addition, the ampoule is free from stickiness and shine, and has excellent durability.
또한, 상기 크림은 피부 도포시 가벼운 밀착감을 부여하고, 피부 흡루력이 우수하여 촉촉하게 스며들며, 최종적으로 매끈하고 끈적임 없는 부드러움을 부여할 수 있다.In addition, the cream imparts a light adherence when applied to the skin, has excellent skin absorption, penetrates into the skin moistly, and finally provides a smooth and non-sticky softness.
또한, 상기 앰플 및 크림은 온도에 의한 변성이 적고, 성분 분리 현상이 없어 보관성이 우수할 수 있다.In addition, the ampoules and creams are less denatured by temperature and have excellent storage stability because there is no component separation.
이하, 하기의 제조예, 실시예 및 실험예를 들어 본 발명을 보다 구체적으로 설명한다. 그러나 이들 제조예, 실시예 및 실험예는 본 발명에 대한 이해를 돕기 위해 예시의 목적으로만 제공된 것일 뿐 본 발명의 범주 및 범위가 하기 예에 의해 제한되는 것은 아니다.Hereinafter, the present invention will be described in more detail with reference to the following preparation examples, examples and experimental examples. However, these preparation examples, examples, and experimental examples are provided only for illustrative purposes to aid understanding of the present invention, and the scope and scope of the present invention are not limited by the following examples.
[제조예] 식물 추출물 및 조성물의 제조[Preparation Example] Preparation of plant extracts and compositions
금화규(꽃, 잎줄기, 뿌리), 율피, 녹차, 해죽순, 곤드레, 마삭줄, 포도, 가지 각각을 믹서를 이용하여 1차적으로 파쇄한 후, 각각 시료 중량의 10배의 70% 에탄올을 첨가하여 실온에서 24시간 침지하여 3회 반복 추출하였다. 각 추출물은 여과 및 농축 후 동결건조하였다.Geumhwagyu (flower, leaf stem, root), yulpi, green tea, sea bamboo shoot, gondre, marsak string, grape, and eggplant are primarily crushed using a mixer, and then 70% ethanol of 10 times the sample weight is added to each. Soaked at room temperature for 24 hours and extracted three times. Each extract was lyophilized after filtration and concentration.
제조된 식물 추출물을 아래 표 3에 기재된 함량비율로 혼합하여 조성물을 제조하였다.A composition was prepared by mixing the prepared plant extracts in the content ratios shown in Table 3 below.
성분ingredient 함량(중량%)Content (% by weight)
금화규 꽃 추출물Geumhwagyu Flower Extract 1010
금화규 잎줄기 추출물Geumhwagyu Leaf Stem Extract 55
금화규 뿌리 추출물Geumhwagyu Root Extract 55
율피 추출물Yulpi Extract 2020
녹차 추출물green tea extract 2020
해죽순 추출물Haejuksun Extract 1010
포도(줄기) 추출물Grape (Stem) Extract 1010
곤드레 추출물gondola extract 1010
가지 추출물eggplant extract 55
마삭줄 추출물Marjoram Extract 55
[실험예] [Experimental Example]
[실험예 1] DPPH 라디칼 소거능 확인[Experimental Example 1] Confirmation of DPPH radical scavenging activity
1,1-디페닐-2-피크릴하이드라질(DPPH)은 화학적으로 안정화된 수용성 프리 라디칼(free radical)로서 517nm에서 특징적인 광흡수를 나타내는 보라색 화합물로 알코올 등의 유기 용매에서 매우 안정하며, 항산화 활성이 있는 물질과 만나면 전자를 내어주면서 라디칼(DPPH)이 소멸되어 최초 용액의 보라색 빛깔에서 노란색으로 색깔이 변화되어 산화 활성을 육안으로도 쉽게 관찰할 수 있어 항산화 활성 실험에 활용되고 있는 대표적인 물질이다. 1,1-diphenyl-2-picrylhydrazyl (DPPH) is a chemically stabilized water-soluble free radical, a purple compound showing characteristic light absorption at 517 nm, and is very stable in organic solvents such as alcohol. When it meets a substance with antioxidant activity, it gives up electrons and radicals (DPPH) are annihilated, and the color changes from purple in the initial solution to yellow, so the oxidation activity can be easily observed with the naked eye, which is a representative substance used in antioxidant activity experiments. to be.
1,1-디페닐-2-피크릴하이드라질(DPPH)를 제조예의 조성물(1000μg/ml)과 혼합하여 반응시킨 후 517nm에서의 흡광도 변화를 측정하였다. 그 결과, 제조예의 조성물을 처리했을 경우에 약 99.63%의 라디칼 소거능을 확인할 수 있었다.After mixing and reacting 1,1-diphenyl-2-picrylhydrazyl (DPPH) with the composition of Preparation Example (1000 μg/ml), the change in absorbance at 517 nm was measured. As a result, when the composition of Preparation Example was treated, it was confirmed that about 99.63% of the radical scavenging ability was obtained.
[실험예 2] ABTS+ 라디칼 소거능 확인[Experimental Example 2] Confirmation of ABTS+ radical scavenging activity
2,2′-Azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) diammonium salt(ABTS)와 과황산칼륨의 혼합물에 제조예의 조성물(1000μg/ml)을 처리하였다. 그 결과, 제조예의 조성물을 처리했을 경우에 약 99.6%의 라디칼 소거능을 나타냈다. 참고로, 제조예 조성물을 100μg/ml 이하로 처리했을 경우에도, 비타민 C 대비하여 70% 수준의 라디칼 소거능을 나타냈다.A mixture of 2,2′-Azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) diammonium salt (ABTS) and potassium persulfate was treated with the composition of Preparation Example (1000 μg/ml). As a result, when the composition of Preparation Example was treated, about 99.6% of the radical scavenging ability was shown. For reference, even when the preparation composition was treated at 100 μg/ml or less, the radical scavenging activity was 70% higher than that of vitamin C.
[실험예 3] 주름 개선 효과 확인[Experimental Example 3] Confirmation of wrinkle improvement effect
[실험예 3-1] Elastase 활성 저해 효과 확인[Experimental Example 3-1] Confirmation of Elastase activity inhibitory effect
Elastase 저해능 측정은 기질로서 N-succinyl-(L-Ala)3-p-nitroanilide를 사용하여 37℃에서 20분간 기질로부터 생성되는 p-nitroanilide의 생성량을 405 nm에서 측정하였다. 즉, 각 시험용액을 일정 농도가 되도록 하여 0.5 mL씩 시험관에 취하고, 50 mM tris-HCl buffer (pH 8.6)에 녹인 porcine pancreas elastase (2.5 U/mL)용액 0.5 mL을 가한 후 기질로 50 mM tris-HCl buffer (pH 8.6)에 녹인 N-succinyl-(L-Ala)3-p-nitroanilide (0.5 mg/mL)을 첨가하여 20분간 반응시켜 측정하였다. elastase 저해능은 시료용액의 첨가군과 무 첨가 군의 흡광도 감소율로 나타내었다. Elastase inhibition was measured at 405 nm for the amount of p-nitroanilide generated from the substrate at 37° C. for 20 minutes using N-succinyl-(L-Ala) 3 -p-nitroanilide as a substrate. That is, 0.5 mL of each test solution is taken in a test tube at a certain concentration, 0.5 mL of a solution of porcine pancreas elastase (2.5 U/mL) dissolved in 50 mM tris-HCl buffer (pH 8.6) is added, and 50 mM tris as a substrate N-succinyl-(L-Ala) 3 -p-nitroanilide (0.5 mg/mL) dissolved in -HCl buffer (pH 8.6) was added and reacted for 20 minutes to measure. The elastase inhibitory ability was expressed as the rate of decrease in absorbance of the sample solution added group and non-added group.
그 결과, 제조예의 조성물(1000μg/ml)을 처리했을 경우에 약 45%의 활성 저해 효과가 있었다. 참고로, 제조예 조성물을 100μg/ml 로 처리했을 경우에는 대조군인 EGCG 보다 약 10% 더 우수한 효과를 나타내었다.As a result, when the composition of Preparation Example (1000 μg/ml) was treated, there was an activity inhibition effect of about 45%. For reference, when the preparation composition was treated with 100 μg/ml, the effect was about 10% better than that of the control EGCG.
[실험예 3-2] Collagenase 활성 저해 효과 확인[Experimental Example 3-2] Collagenase activity inhibitory effect confirmed
Collagenase 저해능 측정은 0.1 M tris-HCl buffer (pH 7.5)에 4 mM CaCl2를 첨가하여, 4-phenylazobenzyloxycarbonyl-Pro-Leu-Gly-Pro-D-Arg (0.3 mg/mL)를 녹인 기질액 0.25 mL 및 시료용액 0.1 mL의 혼합액에 collagenase (0.2 mg/mL) 0.15 mL를 첨가하여 실온에서 20분간 방치한 후 6% citric acid 0.5 mL을 넣어 반응을 정지 시킨 후, ethyl acetate 1.5 mL을 첨가하여 320 nm에서 흡광도를 측정하였다. collagenase 저해능은 시료용액의 첨가군과 무첨가군의 흡광도 감소율로 나타내었다.Collagenase inhibition was measured by adding 4 mM CaCl 2 to 0.1 M tris-HCl buffer (pH 7.5), 0.25 mL of a substrate solution in which 4-phenylazobenzyloxycarbonyl-Pro-Leu-Gly-Pro-D-Arg (0.3 mg/mL) was dissolved. After adding 0.15 mL of collagenase (0.2 mg/mL) to the mixture of 0.1 mL of sample solution and 0.1 mL of sample solution, leave it at room temperature for 20 minutes, stop the reaction by adding 0.5 mL of 6% citric acid, and add 1.5 mL of ethyl acetate to 320 nm. The absorbance was measured at. The collagenase inhibitory ability was expressed as the rate of decrease in absorbance of the sample solution added group and non-added group.
그 결과, 제조예의 조성물(1000μg/ml)을 처리했을 경우에 약 44%의 활성 저해 효과가 있었다. 참고로, 제조예 조성물을 100μg/ml 로 처리했을 경우에는 대조군인 EGCG 효과의 약 60%의 효과(약 24%)를 나타내어, 저농도에서도 콜라게나아제 활성 저해 효과가 우수함을 확인할 수 있었다.As a result, when the composition of Preparation Example (1000 μg/ml) was treated, there was an activity inhibition effect of about 44%. For reference, when the preparation composition was treated with 100 μg / ml, it showed an effect of about 60% (about 24%) of the effect of EGCG, which is a control group, and it was confirmed that the collagenase activity inhibitory effect was excellent even at a low concentration.
[실험예 3-3] 항염 효과 확인[Experimental Example 3-3] Confirmation of anti-inflammatory effect
[실험예 3-3-1] 세포 생존율 확인[Experimental Example 3-3-1] Confirmation of cell viability
제조예의 조성물에 대하여 대식세포(Raw 264.7) 생존율을 확인하였다. 그 결과, 10, 100, 1000 μg/ml의 농도에서 80.2% 이상의 세포 생존율을 확인하였다. 본 실험 결과를 바탕으로, 세포 생존율이 90.1%였던 100 μg/ml이하의 농도의 조성물을 처리하여 아래 실험을 수행하였다.Macrophage (Raw 264.7) viability was confirmed with respect to the composition of Preparation Example. As a result, cell viability of 80.2% or more was confirmed at concentrations of 10, 100, and 1000 μg/ml. Based on the results of this experiment, the following experiment was performed by treating the composition with a concentration of 100 μg / ml or less, which had a cell viability of 90.1%.
[실험예 3-3-2] Nitric oxide 활성 저해 효과 확인[Experimental Example 3-3-2] Confirmation of nitric oxide activity inhibition effect
마우스 대식세포 세포주인 Raw 264.7(mouse macrophage cell line RAW 264.7)에 대식세포 자극인자인 LPS(lipopolysaccharide)를 처리하여 염증물질인 NO 생성을 유도하고, 제조예의 조성물을 1, 5, 10, 100μg/ml로 24시간 처리하였다. 이후, 그리스 시약(Griess reagent)을 첨가하여 10분간 반응시킨 다음 마이크로플레이트-ELISA 리더(microplate-ELISA reader)를 이용하여 540 nm 파장에서 NO 생성을 측정하였다. 그 결과, 100 μg/ml의 농도로 처리했을 경우, 51.6%의 NO가 측정되어, 48.4%의 NO 생성 저해능이 있음을 확인할 수 있었다. 참고로, 대조군인 100 μg/ml의 EGCG를 처리했을 경우엔 66.4%의 NO 생성 억제 효과를 나타내어, 본 발명의 조성물이 EGCG 대비 약 73%의 NO 생성 억제 효과를 나타냄을 확인하였다.Mouse macrophage cell line Raw 264.7 (mouse macrophage cell line RAW 264.7) was treated with lipopolysaccharide (LPS), a macrophage stimulating factor, to induce NO production, an inflammatory substance, and the composition of Preparation Example was 1, 5, 10, 100 μg/ml treated for 24 hours. Thereafter, a Griess reagent was added and reacted for 10 minutes, and NO generation was measured at a wavelength of 540 nm using a microplate-ELISA reader. As a result, when treated at a concentration of 100 μg/ml, 51.6% of NO was measured, confirming that 48.4% of NO production inhibition was present. For reference, when treated with 100 μg/ml of EGCG as a control, it was confirmed that the composition of the present invention exhibited an effect of inhibiting NO production by about 73% compared to EGCG.
[실험예 3-3-3] PGE2 발현 억제 효과 확인[Experimental Example 3-3-3] Confirmation of PGE 2 expression inhibitory effect
PGE2는 NO와 마찬가지로 손상된 부위나 조직에서 통증과 발열의 전달에 주로 관여하는 염증 매개 물질이다.Like NO, PGE 2 is an inflammatory mediator mainly involved in the transmission of pain and fever in damaged areas or tissues.
Raw 264.7 세포를 5×104 cells/mL 로 조절한 후 96well plate에 seeding하고 24시간 동안 전 배양하였다. 세포에 1μg/mL의 LPS와 추출물을 동시에 처리하여 24시간 재배양한 후 세포배양액내의 PGE2 cytokine의 분비량은 enzyme linked immunosorbent assay (ELISA) kit (R&D Systems, Minneapolis, MN, USA)를 이용하여 측정하였다. 배양액을 goat anti-mouse로 coating된 96well plate에 각각 100㎕씩 loading하고, primary antibody solution 50㎕와 PGE2 conjugate 50㎕씩 첨가하여 500rpm에서 shaking하면서 2시간 동안 실온 반응시켰다. 그 후 Washing buffer로 4회 세척하고 substrate solution을 처리한 후 450nm에서 흡광도를 측정하였다. Raw 264.7 cells were adjusted to 5×10 4 cells/mL, seeded in a 96-well plate, and pre-incubated for 24 hours. Cells were simultaneously treated with 1 μg/mL of LPS and the extract and cultured for 24 hours. The secretion of PGE 2 cytokine in the cell culture medium was measured using an enzyme linked immunosorbent assay (ELISA) kit (R&D Systems, Minneapolis, MN, USA) did 100 μl each of the culture medium was loaded onto a 96-well plate coated with goat anti-mouse, and 50 μl of primary antibody solution and 50 μl of PGE 2 conjugate were added, followed by shaking at 500 rpm and reacting at room temperature for 2 hours. After that, it was washed 4 times with Washing buffer, treated with substrate solution, and absorbance was measured at 450 nm.
그 결과, 제조예의 조성물 100μg/ml을 처리했을 경우, 37.1%의 높은 PGE2 생성 저해능을 확인할 수 있었다. 참고로, 대조군인 EGCG의 경우 동량 처리했을 경우, 약 61.2%의 억제 효과를 나타내어, 본 발명의 조성물이 대조군 대비 약 61%의 억제 효과가 있음을 확인할 수 있었다.As a result, when 100 μg/ml of the composition of Preparation Example was treated, a high PGE 2 production inhibitory ability of 37.1% was confirmed. For reference, when the same amount of EGCG as a control group was treated, it showed an inhibitory effect of about 61.2%, and it was confirmed that the composition of the present invention had an inhibitory effect of about 61% compared to the control group.
[비교 실험예][Comparative Experimental Example]
[비교 실험예 1] 추출물 조합에 따른 효과 차이 확인[Comparative Experimental Example 1] Check the effect difference according to the extract combination
하기 표 4와 같은 조합의 추출물을 사용하여, 실험예와 동일한 실험을 수행하였다. 사용된 추출물은 모두 동량을 혼합하였다. 결과는 표 5에 기재된 바와 같다.The same experiment as in Experimental Example was performed using the extracts of the combinations shown in Table 4 below. All of the extracts used were mixed in equal amounts. The results are as shown in Table 5.
실험군 번호experimental group number 금화규Geumhwagyu 율피Yulpi 녹차green tea 해죽순Haejuksun 곤드레gondre 마삭줄finishing line 포도grape 가지egg plant
1One ○○ -- -- -- -- -- -- --
22 -- ○○ -- -- -- -- -- --
33 -- -- ○○ -- -- -- -- --
44 -- -- -- ○○ -- -- -- --
55 -- -- -- -- ○○ -- -- --
66 -- -- -- -- -- ○○ -- --
77 -- -- -- -- -- -- ○○ --
88 -- -- -- -- -- -- -- ○○
99 ○○ ○○ -- -- -- -- -- --
1010 ○○ -- ○○ -- -- -- -- --
1111 ○○ -- -- ○○ -- -- -- --
1212 ○○ -- -- -- ○○ -- -- --
1313 ○○ -- -- -- -- ○○ -- --
1414 ○○ -- -- -- -- -- ○○ --
1515 ○○ -- -- -- -- -- -- ○○
1616 ○○ ○○ ○○ ○○ ○○ ○○ -- --
1717 ○○ ○○ ○○ ○○ ○○ ○○ ○○ ○○
실험군 번호experimental group number DPPH assay(%)DPPH assay (%) ABTS+ assay(%)ABTS+ assay (%) Ellatase 억제율(%)Ellatase inhibition rate (%) Collagenase 억제율(%)Collagenase inhibition rate (%) NO 생성 억제율(%)NO production inhibition rate (%) PGE2 생성 억제율(%)PGE 2 generation inhibition rate (%)
1One 78.278.2 91.291.2 3131 31.2%31.2% 32.532.5 25.525.5
22 89.389.3 89.189.1 33.233.2 33%33% 33.533.5 29.629.6
33 91.191.1 89.089.0 33.533.5 32.3%32.3% 34.134.1 29.929.9
44 86.586.5 90.090.0 32.532.5 31.731.7 3434 28.728.7
55 62.562.5 65.565.5 23.423.4 22.722.7 25.825.8 23.123.1
66 28.728.7 21.621.6 11.811.8 9.69.6 10.210.2 10.510.5
77 87.287.2 87.187.1 32.232.2 32.832.8 33.133.1 28.328.3
88 18.918.9 35.235.2 10.210.2 1010 12.412.4 7.77.7
99 85.385.3 90.190.1 31.831.8 3333 34.234.2 27.627.6
1010 90.190.1 93.193.1 3333 33.233.2 34.534.5 29.529.5
1111 85.285.2 93.193.1 32.732.7 31.731.7 34.834.8 28.328.3
1212 75.375.3 84.484.4 31.631.6 32.132.1 32.132.1 24.724.7
1313 62.262.2 65.265.2 29.329.3 27.327.3 25.525.5 22.822.8
1414 90.090.0 92.192.1 34.234.2 32.532.5 34.934.9 29.129.1
1515 56.656.6 71.471.4 2323 22.322.3 23.723.7 21.521.5
1616 93.393.3 94.594.5 35.935.9 34.534.5 35.535.5 30.830.8
1717 97.597.5 96.596.5 3939 3737 39.539.5 31.231.2
단위: %unit: %
[비교 실험예 2] 금화규 꽃, 잎줄기 및 뿌리 추출물의 함량에 따른 효과 확인[Comparative Experimental Example 2] Confirmation of effect according to the content of Geumhwagyu flower, leaf stem and root extract
아래 표 6과 같이 꽃, 잎줄기, 및 뿌리 추출물의 함량비를 조절하여, 실험예와 동일한 실험을 수행하고, 결과를 표 7에 기록하였다.As shown in Table 6 below, the same experiment as in Experimental Example was performed by adjusting the content ratio of the flower, leaf stem, and root extract, and the results were recorded in Table 7.
실험군 번호experimental group number 꽃flower 잎줄기leaf stalk 뿌리Root
1818 1One 1One 1One
1919 2.52.5 1One 1One
2020 0.50.5 1One 1One
2121 22 0.50.5 1One
2222 22 1.51.5 1One
실험군 번호experimental group number DPPH assay(%)DPPH assay (%) ABTS+ assay(%)ABTS+ assay (%) Ellatase 억제율(%)Ellatase inhibition rate (%) Collagenase 억제율(%)Collagenase inhibition rate (%) NO 생성 억제율(%)NO production inhibition rate (%) PGE2 생성 억제율(%)PGE 2 generation inhibition rate (%)
1818 95.295.2 94.394.3 4040 40.240.2 42.742.7 30.830.8
1919 94.794.7 94.294.2 39.539.5 39.739.7 41.541.5 30.130.1
2020 93.293.2 93.793.7 38.838.8 38.538.5 40.240.2 29.529.5
2121 95.195.1 94.194.1 39.839.8 40.140.1 41.241.2 29.929.9
2222 94.794.7 94.294.2 40.540.5 41.541.5 40.840.8 3232
[비교 실험예 3] 율피, 녹차, 해죽순, 포도, 곤드레, 가지, 및 마삭줄 추출물의 함량에 따른 효과 확인[Comparative Experimental Example 3] Yulpi, green tea, haejuksun, grape, gondre, eggplant, and check the effect according to the content of the extract
아래 표 8과 같이 율피, 녹차, 해죽순, 포도, 곤드레, 가지, 및 마삭줄 추출물의 함량비를 조절하여, 실험예와 동일한 실험을 수행하고, 결과를 표 9에 기록하였다.As shown in Table 8 below, the same experiment as in Experimental Example was performed by adjusting the content ratio of extracts of yulpi, green tea, sea bamboo shoots, grapes, gondre, eggplant, and marsak line, and the results are recorded in Table 9.
실험군 번호experimental group number 금은화 gold and silver coins 율피Yulpi 녹차green tea 해죽순Haejuksun 포도grape 곤드레 gondre 가지egg plant 마삭줄finishing line
2323 1One 0.50.5 1One 0.50.5 0.50.5 0.50.5 0.250.25 0.250.25
2424 1One 2.52.5 1One 0.50.5 0.50.5 0.50.5 0.250.25 0.250.25
2525 1One 1One 0.50.5 0.50.5 0.50.5 0.50.5 0.250.25 0.250.25
2626 1One 1One 2.52.5 0.50.5 0.50.5 0.50.5 0.250.25 0.250.25
2727 1One 1One 1One 0.10.1 0.50.5 0.50.5 0.250.25 0.250.25
2828 1One 1One 1One 22 0.50.5 0.50.5 0.250.25 0.250.25
2929 1One 1One 1One 0.50.5 0.10.1 0.50.5 0.250.25 0.250.25
3030 1One 1One 1One 0.50.5 22 0.50.5 0.250.25 0.250.25
3131 1One 1One 1One 0.50.5 0.50.5 0.10.1 0.250.25 0.250.25
3232 1One 1One 1One 0.50.5 0.50.5 22 0.250.25 0.250.25
3333 1One 1One 1One 0.50.5 0.50.5 0.50.5 0.10.1 0.250.25
3434 1One 1One 1One 0.50.5 0.50.5 0.50.5 0.50.5 0.250.25
3535 1One 1One 1One 0.50.5 0.50.5 0.50.5 0.50.5 0.10.1
3636 1One 1One 1One 0.50.5 0.50.5 0.50.5 0.50.5 0.50.5
실험군 번호experimental group number DPPH assayDPPH assay ABTS+ assayABTS+ assay Ellatase 억제율Ellatase inhibition rate Collagenase 억제율Collagenase inhibition rate NO 생성 억제율NO production inhibition rate PGE2 생성 억제율Inhibition rate of PGE 2 production
2323 95.295.2 94.894.8 37.537.5 36.536.5 42.142.1 32.532.5
2424 94.294.2 94.094.0 36.836.8 36.236.2 41.741.7 31.731.7
2525 93.893.8 93.593.5 39.239.2 38.538.5 40.540.5 31.831.8
2626 94.694.6 94.194.1 38.438.4 37.537.5 41.041.0 30.830.8
2727 92.592.5 91.591.5 39.539.5 38.838.8 42.242.2 32.832.8
2828 93.893.8 92.492.4 40.240.2 39.939.9 41.741.7 30.130.1
2929 95.295.2 94.394.3 38.838.8 37.737.7 43.843.8 33.533.5
3030 94.194.1 93.793.7 37.237.2 36.536.5 42.742.7 31.431.4
3131 93.893.8 93.193.1 36.536.5 36.736.7 40.540.5 31.731.7
3232 93.793.7 93.593.5 37.737.7 37.837.8 41.741.7 30.930.9
3333 93.293.2 92.792.7 35.635.6 35.135.1 41.541.5 32.132.1
3434 94.294.2 93.793.7 36.636.6 36.236.2 41.741.7 30.830.8
3535 93.893.8 93.193.1 38.238.2 37.537.5 42.742.7 31.731.7
3636 94.794.7 94.194.1 39.539.5 38.938.9 41.941.9 30.630.6

Claims (11)

  1. 금화규 추출물; 및 Geumhwagyu extract; and
    밤 추출물, 녹차 추출물, 해죽순 추출물, 곤드레 추출물, 및 마삭줄 추출물 중 하나 이상을 유효 성분으로 포함하는, 항산화용 조성물.A composition for antioxidant comprising at least one of a chestnut extract, green tea extract, haejuksun extract, gondre extract, and marjoram extract as an active ingredient.
  2. 금화규 추출물; 및 Geumhwagyu extract; and
    밤 추출물, 녹차 추출물, 해죽순 추출물, 곤드레 추출물, 및 마삭줄 추출물 중 하나 이상을 유효 성분으로 포함하는, 피부 주름 개선용 조성물.A composition for improving skin wrinkles, comprising at least one of a chestnut extract, green tea extract, haejuksun extract, gondre extract, and marjoram extract as an active ingredient.
  3. 금화규 추출물; 및 Geumhwagyu extract; and
    밤 추출물, 녹차 추출물, 해죽순 추출물, 곤드레 추출물, 및 마삭줄 추출물 중 하나 이상을 유효 성분으로 포함하는, 항염증용 조성물.An anti-inflammatory composition comprising at least one of a chestnut extract, green tea extract, haejuksun extract, gondre extract, and marjoram extract as an active ingredient.
  4. 제1항 내지 제3항 중 어느 한 항에 있어서,According to any one of claims 1 to 3,
    상기 금화규 추출물은,The Geumhwagyu extract,
    꽃 추출물, 잎줄기 추출물, 및 뿌리 추출물 중 하나 이상을 포함하는, 조성물.A composition comprising at least one of a flower extract, a leaf stem extract, and a root extract.
  5. 제4항에 있어서,According to claim 4,
    상기 금화규 꽃 추출물 및 잎줄기 추출물은 각각 순서대로, The gold flower extract and leaf stem extract are each in order,
    뿌리 추출물 100 중량부를 기준으로, 150~250 중량부 및 50~150 중량부로 포함되는, 조성물.A composition comprising 150 to 250 parts by weight and 50 to 150 parts by weight based on 100 parts by weight of the root extract.
  6. 제1항 내지 제3항 중 어느 한 항에 있어서,According to any one of claims 1 to 3,
    상기 조성물은, The composition,
    포도 추출물 및 가지(eggplant) 추출물 중 하나 이상을 더 포함하는, 조성물.A composition further comprising at least one of grape extract and eggplant extract.
  7. 제1항 내지 제3항 중 어느 한 항에 있어서,According to any one of claims 1 to 3,
    상기 밤 추출물은, 율피 추출물을 포함하는, 조성물.The chestnut extract, composition comprising a yulpi extract.
  8. 제1항 내지 제3항 중 어느 한 항에 있어서,According to any one of claims 1 to 3,
    밤 추출물 및 녹차 추출물은, 금화규 추출물을 100 중량부로 할 때, 각각 50~200 중량부로 포함되고, Chestnut extract and green tea extract are included in 50 to 200 parts by weight, respectively, based on 100 parts by weight of Geumhwagyu extract,
    해죽순 추출물 및 곤드레 추출물은, 금화규 추출물을 100 중량부로 할 때, 각각 10~100 중량부로 포함되며, Haejuksun extract and gondre extract are included in 10 to 100 parts by weight, respectively, based on 100 parts by weight of Geumhwagyu extract,
    마삭줄 추출물은, 금화규 추출물을 100 중량부로 할 때, 1~50 중량부로 포함되는, 조성물.The composition, which is contained in 1 to 50 parts by weight, when the geumhwagyu extract is 100 parts by weight.
  9. 제6항에 있어서,According to claim 6,
    상기 포도 추출물은, 금화규 추출물을 100 중량부로 할 때, 10~100 중량부로 포함되고,The grape extract is included in 10 to 100 parts by weight based on 100 parts by weight of the Keumhwagyu extract,
    상기 가지 추출물은, 금화규 추출물을 100 중량부로 할 때, 1~50 중량부로 포함되는, 조성물.Wherein the eggplant extract is contained in an amount of 1 to 50 parts by weight based on 100 parts by weight of the extract of Geumhwagyu.
  10. 제1항 내지 제3항 중 어느 한 항에 있어서,According to any one of claims 1 to 3,
    상기 조성물은, 식품 조성물 또는 화장료 조성물을 포함하는, 조성물.The composition, a composition comprising a food composition or a cosmetic composition.
  11. 제10항에 있어서,According to claim 10,
    상기 화장료 조성물은, 크림 또는 앰플을 포함하는, 조성물.The cosmetic composition, a composition comprising a cream or an ampoule.
PCT/KR2021/008381 2021-07-01 2021-07-01 Antioxidant composition comprising oriental medicinal extract containing aurea helianthus, and herbal medicine extract WO2023277224A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/KR2021/008381 WO2023277224A1 (en) 2021-07-01 2021-07-01 Antioxidant composition comprising oriental medicinal extract containing aurea helianthus, and herbal medicine extract

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/KR2021/008381 WO2023277224A1 (en) 2021-07-01 2021-07-01 Antioxidant composition comprising oriental medicinal extract containing aurea helianthus, and herbal medicine extract

Publications (1)

Publication Number Publication Date
WO2023277224A1 true WO2023277224A1 (en) 2023-01-05

Family

ID=84692805

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2021/008381 WO2023277224A1 (en) 2021-07-01 2021-07-01 Antioxidant composition comprising oriental medicinal extract containing aurea helianthus, and herbal medicine extract

Country Status (1)

Country Link
WO (1) WO2023277224A1 (en)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070021522A (en) * 2005-08-18 2007-02-23 한불화장품주식회사 Cosmetic composition containing extract of cirsium setidens
US20090285913A1 (en) * 2006-07-03 2009-11-19 Jeong Min Lee Trachelospermi Caulis Extract Composition for the Treatment and Prevention of Inflammatory Diseases
KR100955388B1 (en) * 2009-05-25 2010-04-29 (주)바이오에프디엔씨 Cosmetic composition for anti-inflammation and anti-aging and preparing the same
KR20170135078A (en) * 2016-05-30 2017-12-08 세명대학교 산학협력단 Composition of skin external application containing Chestnut Inner Bark extract and medicinal plants extract
KR20190036388A (en) * 2017-09-27 2019-04-04 주식회사 코씨드바이오팜 Cosmetic composition with extract of Nypa fruticans Wurmb. Fruit
KR20210042445A (en) * 2019-10-10 2021-04-20 주식회사 셀드로우 Cosmetic composition for hair loss care applied to the natural plant composite material extract

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070021522A (en) * 2005-08-18 2007-02-23 한불화장품주식회사 Cosmetic composition containing extract of cirsium setidens
US20090285913A1 (en) * 2006-07-03 2009-11-19 Jeong Min Lee Trachelospermi Caulis Extract Composition for the Treatment and Prevention of Inflammatory Diseases
KR100955388B1 (en) * 2009-05-25 2010-04-29 (주)바이오에프디엔씨 Cosmetic composition for anti-inflammation and anti-aging and preparing the same
KR20170135078A (en) * 2016-05-30 2017-12-08 세명대학교 산학협력단 Composition of skin external application containing Chestnut Inner Bark extract and medicinal plants extract
KR20190036388A (en) * 2017-09-27 2019-04-04 주식회사 코씨드바이오팜 Cosmetic composition with extract of Nypa fruticans Wurmb. Fruit
KR20210042445A (en) * 2019-10-10 2021-04-20 주식회사 셀드로우 Cosmetic composition for hair loss care applied to the natural plant composite material extract

Similar Documents

Publication Publication Date Title
WO2013027984A2 (en) Cosmetic composition containing green tea component
EP1991222B1 (en) Melatonin and immunostimulating substance-based compositions
WO2011122869A2 (en) Cosmetic composition comprising coumestrol or a bean extract containing coumestrol for skin care
KR20100129689A (en) Use of a polyphenol-rich plant extract as antioxidant in combination with a hydrating or humectant agent
FR2684300A1 (en) COSMETIC OR PHARMACEUTICAL COMPOSITION, PARTICULARLY DERMATOLOGICAL, IN PARTICULAR FOR PROMOTING THE PIGMENTATION OF SKIN OR HAIR, CONTAINING A BALLOTE EXTRACT, AND METHOD FOR PRODUCING THE SAME.
FR2767057A1 (en) USE OF GINSENOSIDE RB1 AS AN AGENT FOR STIMULATING THE SYNTHESIS OF ELASTINE
KR20080001791A (en) Skin anti-wrinkle cosmetics composition containing forsythiae fruit extract
WO2017043670A1 (en) Cosmetic composition containing citron extract
KR20200053815A (en) A cosmetic composition for improving skin containing a peptide
KR100994987B1 (en) Cosmetic composition with the calming effect for skins
KR101871927B1 (en) Skin external composition containing sugar apple seed extract
KR101854446B1 (en) Cosmetic composition containing sageretia theezans extracts and spicule powder
KR20130040316A (en) Cosmetics composites
KR20080061080A (en) Cosmetic composition comprising tuber melanosporum
EP0602029B1 (en) Cosmetic or pharmaceutical composition containing an extract of coleus esquirollii, coleus scutellarioides or coleus xanthanthus
JP3998085B2 (en) Hyaluronic acid amount increase accelerator
KR100371504B1 (en) Cosmetics composition comprising extract powder with vitis vinifera l.fermented solution and having whitening and anti-wrinkle effect
WO2023277224A1 (en) Antioxidant composition comprising oriental medicinal extract containing aurea helianthus, and herbal medicine extract
KR102464203B1 (en) Anti-oxidant composition comprising oriental medicine extract containing Hibiseu Smanihot L. and herbal extract
WO2022092337A1 (en) Cosmetic composition containing gynostemma pentaphyllum fermented extract
KR102289551B1 (en) A skin-care agent containing hyaluronic acid complex
JP2000256175A (en) Cosmetic composition
KR100427556B1 (en) Makeup composition containing rucinol
KR101114499B1 (en) Mixed herb medicine extracts of ficus stipulacea thunb. and lespedeza cuneata g. don for skin-whitening and anti-aging and cosmetic compositions containing the same
KR20080029037A (en) Cosmetic composition for whitening the skin comprising the extract of ilex rotunda as active ingredient

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21948524

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE